MITSUBISHI TANABE PHARMA CORP.

Company Snapshot

Founded: 1933

Entity Type: Private

Employees: 5,577

Region: Japan

Headquarter: Osaka, Japan

Key Geographics: Japan

Corporate Address: 3-2-10, Dosho-machi, Chuo-ku, Osaka, 541-8505, Japan Tel. +81-6-6205-5085 www.mt-pharma.co.jp/e/

Company Overview

Mitsubishi Tanabe Pharma is a pharmaceutical company that engages in manufacturing, production and sales of pharmaceutical products.

Mitsubishi Tanabe Pharma discovered numerous innovative pharmaceutical drugs, and it is currently focused on five major disease areas: central nervous system, autoimmune, diabetes, kidney and vaccines. The company aims to discover and develop top-quality and affordable medicines to treat patients who suffer from these diseases. Key drugs include Gilenya, Lexapro, Simponi, Imusera, Telavic, Tenelia, Tetrabik, Invokana and Rupafin, which are used in the treatment of allergic disorders, type 2 diabetes mellitus, chronic hepatitis C, multiple sclerosis, depression and rheumatoid arthritis.

Mitsubishi Tanabe Pharma started clinical preliminaries to acquire POC in the U.S. and Europe for numerous drug candidates, such as MT-7117, which is used to treat erythropoietic protoporphyria disease; and MT-8554, which is used to treat the vasomotor symptoms associated with menopause. The company is also leading several clinical trials for product candidates in early stages, such as MT-0814, which is used in the treatment of ophthalmologicals disease; MT-2990, which is used in the treatment of inflammatory diseases and autoimmune diseases; and MT-4129 medicine which is used in the treatment of cardiovascular system disease.